The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | SAR’579, a trifunctional anti-CD123 NK cell engager, in R/R AML, B-ALL, and HR-MDS
Ashish Bajel, MBBS, FRACP, FRCPA, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia, presents the findings from a first-in-human study (NCT05086315) of SAR443579 (SAR’579), a trifunctional anti-CD123 natural killer (NK) cell engager, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) or higher-risk myelodysplastic syndromes (HR-MDS). This agent targets the CD123 antigen on leukemia cells, and leverages NK-cell mediated killing of the cell. To date, the drug has been well tolerated and has led to blast reduction across all dose levels. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
